Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a member of the ROR receptor family, which includes two closely related type I transmembrane proteins, ROR1 and ROR2. The extracellular domain of ROR1 contains an immunoglobulin-like domain, a cysteine-rich domain, and a Kringle domain. A single transmembrane helix connects the extracellular domain to the cytoplasmic region, which consists of a tyrosine kinase-like or pseudokinase domain, two serine/threonine-rich domains, and a proline-rich domain inserted between them. ROR1 is expressed at low levels or not at all in normal human tissues but is highly expressed in various malignancies, such as chronic lymphocytic leukemia, breast cancer, ovarian cancer, melanoma, and lung adenocarcinoma. This differential expression pattern makes ROR1 a highly promising target for tumor-targeted therapy. FITC-labeled ROR1 Fc chimera protein can be used to quantitatively detect ROR1 protein expression levels and binding activity, providing a technical tool for tumor-targeted therapy research.
ROR1 belongs to the Wnt signaling pathway receptor family and plays a crucial role in various physiological processes by mediating non-canonical Wnt signaling, including regulating cell division, proliferation, migration, and chemotaxis. Wnt5a is a typical activator of the non-canonical Wnt signaling pathway and is involved in the phosphorylation of the NF-κB subunit p65, activating the NF-κB pathway in tumor cells and promoting cell migration, invasion, epithelial-mesenchymal transition, and cancer metastasis. As a receptor for Wnt5a, ROR1 participates in activating the NF-κB pathway in tumor cells. By mediating these signaling pathways, ROR1 plays a key role in tumor initiation and progression. FITC-labeled ROR1 Fc chimera protein can be used to study the interaction between ROR1 and Wnt5a, providing a quantitative analysis tool for mechanistic research.
In recent years, significant progress has been made in monoclonal antibody therapy targeting ROR1. Zilovertamab, a monoclonal antibody targeting ROR1, has demonstrated excellent clinical efficacy in combination therapies. In the treatment of mantle cell lymphoma, the combination therapy achieved an overall response rate (ORR) of 85.2%, with a complete response (CR) rate of 40.7% and a partial response (PR) rate of 44.4%. Remarkable efficacy was also observed in patients with p53 mutations and highly proliferative tumors (high Ki67). In chronic lymphocytic leukemia, the combination therapy yielded an ORR of 91.2% and a CR rate of 8.8%. Compared to monotherapy, the combination therapy showed better progression-free survival, and clinical studies are set to commence. These results highlight the immense potential of ROR1-targeting monoclonal antibodies in treating hematologic malignancies. FITC-labeled ROR1 Fc chimera protein can be used to evaluate the binding capacity of monoclonal antibodies to ROR1 antigens and validate their functional activity.
Antibody-drug conjugates (ADCs) targeting ROR1 represent an important direction in ROR1-targeted therapy. ADCs using Zilovertamab as the antibody scaffold have shown promising efficacy in treating relapsed or refractory non-Hodgkin lymphoma, with an overall ORR of 33.3% and a CR rate of 9.8%. In patients with diffuse large B-cell lymphoma, the ORR was 38.5%, and the CR rate was 23.1%. For mantle cell lymphoma patients, the ORR reached 52.9%, with a CR rate of 11.8%. Among patients who had previously received CAR-T or CAR-NK therapy, the ORR was 40%, and the CR rate was 13.3%. These clinical data demonstrate that ROR1-targeting ADCs exhibit antitumor activity against various B-cell malignancies, particularly in patients who have failed other treatments. The low expression of ROR1 in normal tissues provides ADCs with a favorable safety window.
The development of bispecific antibodies targeting ROR1 has also shown preliminary efficacy. Bispecific antibodies simultaneously bind ROR1 and CD3 on T cells, redirecting T cells to ROR1-positive tumor cells and mediating specific cytotoxicity. This strategy has demonstrated antitumor activity in preclinical and early clinical studies, though further validation in larger patient cohorts is needed. ROR1-targeting CAR-T cell therapy is another important research direction. The high expression of ROR1 in various solid tumors and hematologic malignancies makes it an ideal target for CAR-T cell therapy. Preclinical studies have shown that ROR1 CAR-T cells can effectively eliminate ROR1-positive tumor cells. FITC-labeled ROR1 Fc chimera protein can be used to assess the binding capacity of bispecific antibodies and CAR-T cells to ROR1 antigens and validate their functional activity.
As a member of the receptor tyrosine kinase-like orphan receptor family, ROR1 is gaining increasing attention in the field of tumor-targeted therapy. Its low expression in normal tissues and high expression in various malignancies make it a promising target for future cancer therapies. FITC-labeled ROR1 Fc chimera protein provides a sensitive and efficient detection tool for studying ROR1 protein expression, distribution, and interactions, with applications in antibody screening, CAR-T cell functional evaluation, and immune monitoring.
Nanjing UA-Bio Technology Co., Ltd. (UA-Bio) has independently developed the "FITC-Labeled ROR1 Fc Chimera Protein, Human" (Catalog No.: UA011277), a high-performance green fluorescent-labeled probe specifically designed for ROR1-targeted research and the evaluation of immunotherapy for hematologic and solid tumors. ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a receptor expressed during embryogenesis and abnormally overexpressed in various malignancies (e.g., chronic lymphocytic leukemia [CLL], mantle cell lymphoma [MCL], acute lymphoblastic leukemia [ALL], breast cancer, lung cancer, ovarian cancer, pancreatic cancer, etc.), making it an ideal target for ADC drugs, CAR-T cell therapy, and bispecific antibodies.
| Core Product Advantages | Detailed Parameters / Functional Description |
|---|---|
| High Purity and Intact Biological Activity | The product is produced using internationally advanced eukaryotic expression systems and highly standardized purification processes, validated through multi-dimensional quality control to ensure >95% purity and correct native conformation (retaining intact glycosylation modifications). The Fc chimera format enhances protein stability and proper folding. The FITC labeling process is optimized to ensure high labeling efficiency while maintaining high-affinity binding to antibodies, accurately mimicking the antigenic properties of ROR1 on the surface of various tumor cells under physiological conditions.-- |
| High-Brightness FITC Labeling | An optimized FITC labeling ratio ensures stable fluorescence dye labeling per ROR1-Fc chimera protein molecule, producing bright green fluorescence signals under 488 nm excitation. This makes it suitable for flow cytometry (FACS) and fluorescence microscopy, providing reliable support for the activity evaluation and precise quantification of ROR1-targeting molecules.-- |
| Exceptional Batch Consistency and Stability | Strict management from protein expression and labeling to purification and quality control, combined with a comprehensive release testing system, ensures stable binding activity, consistent fluorescence intensity, and excellent long-term stability for each batch. This provides solid and reliable quality assurance for long-term and continuous ROR1-targeted research.-- |
| Ideal Tool for Multiple Applications | This protein performs excellently in various application systems, including CAR-T cell positivity rate detection by flow cytometry (supporting multicolor panel design), anti-ROR1 antibody/antagonist screening, competitive binding assays, hematologic/solid tumor marker analysis, and flow cytometry. It is widely applicable to ROR1-targeted CAR-T cell therapy product development, tumor immunotherapy research, and drug activity evaluation.-- |
| Comprehensive Solutions and Professional Support | We provide thoroughly validated standard experimental protocols, typical flow cytometry data, and detailed result interpretation guidelines to help you quickly establish stable and reproducible ROR1-targeting molecule detection workflows. The Nanjing UA-Bio technical team offers professional technical consultation and support throughout your research design, experimental optimization, and data analysis.-- |
Nanjing UA-Bio Technology Co., Ltd. is committed to providing cutting-edge, high-quality core reagents and tools for immunology, cell therapy, and innovative drug development. For detailed technical parameters, validation data, or specific application inquiries regarding the "FITC-Labeled ROR1 Fc Chimera Protein, Human" (Catalog No.: UA011277), please feel free to contact us.
